Propranolol is non cardioselective
beta blocker used to treat various cardiac and non-cardiac diseases including arrhythmia, hypertension, portal hypertension and oesophageal varices.
Metoprolol, a cardioselective
beta-blocker, is a risk for intrauterine growth restriction (IUGR) in the second/third trimesters.
SOM3355, a repositioned drug previously approved for another indication, is a cardioselective
?1-adrenoceptor antagonist discovered in the US, launched in several European countries, and currently commercialized in some Asian countries for the treatment of hypertension and angina pectoris.
To normalize blood pressure, she was administered 100 mg labetalol, a cardioselective
beta blocker, twice a day in addition to a previous antihypertensive regime, which brought her blood pressure down to 146/88 mmHg in 6 days.
The use of [beta]-blockers in the management of cardiac disease, while a theoretical concern in patients with increased airway resistance, is generally safe with the use of cardioselective
The cumulative evidence from trials and meta-analysis indicates that cardioselective
BBs should not be withheld in patients with reactive airway disease or COPD.
Also, recent large observational studies provide some evidence that concomitant long-term use of inhaled antimuscarinic agents or beta agonists along with cardioselective
beta blockers actually reduces mortality rates and the risk of exacerbations in patients with COPD (54,55).
Nandibewoor, "Electroanalysis of cardioselective
beta-adrenoreceptor blocking agent acebutolol by disposable graphite pencil electrodes with detailed redox mechanism," Cogent Chemistry, vol.
Nebivolol is a highly cardioselective
3rd-generation long acting -1 blocker which is usually prescribed once a day as monotherapy or in combination with other antihypertensive drugs.
Toprol-XL is a cardioselective
beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long term treatment of angina pectoris and treatment of stable, symptomatic (NYHA class II or III) heart failure of specific origins.
In various studies, etomidate has shown less cardiovascular depression and therefore minimise the use of vasopressor agent than other induction agent in sepsis and critically ill patients (.3,4,5,6) Although, etomidate can cause adrenal insufficiency in postoperative period, but clinical consequences of that is still unclear over its advantage to prevent hypotension (Cardioselective
property) at induction.
* Cross-sectional study of 279,669 physicians that received industry-sponsored meals (retrieved from Open Payments program) and wrote Medicare part D prescriptions in any of four drug classes: statins, cardioselective
blockers, angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers (ACE inhibitors and ARBs) and selective serotonin reuptake inhibitors (SSRIs)/ serotonin norepinephrine reuptake inhibitors (SNRIs)